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Abstract
Aims To investigate whether serum uric acid predicts adverse outcomes in persons with indices of diastolic dysfunction in a
general population.
Methods and results We performed a prospective cohort study among 1460 women and 1480 men from 1994 to 2013. End-
points were all-cause mortality, incident myocardial infarction, and incident ischaemic stroke. We stratiﬁed the analyses by
echocardiographic markers of diastolic dysfunction, and uric acid was the independent variable of interest. Hazard ratios (HR)
were estimated per 59 μmol/L increase in baseline uric acid. Multivariable adjusted Cox proportional hazards models showed that
uric acid predicted all-cause mortality in subjects with E/A ratio <0.75 (HR 1.12, 95% conﬁdence interval [CI] 1.00–1.25) or E/A
ratio >1.5 (HR 1.51, 95% CI 1.09–2.09, P for interaction between E/A ratio category and uric acid = 0.02). Elevated uric acid
increased mortality risk in persons with E-wave deceleration time <140 ms or >220 ms (HR 1.46, 95% CI 1.01–2.12 and HR
1.13, 95% CI 1.02–1.26, respectively; P for interaction = 0.04). Furthermore, in participants with isovolumetric relaxation time
≤60ms, mortality risk was higher with increasing uric acid (HR 4.98, 95% CI 2.02–12.26, P for interaction = 0.004). Finally, elevated
uric acid predicted ischaemic stroke in subjects with severely enlarged left atria (HR 1.62, 95% CI 1.03–2.53, P for
interaction = 0.047).
Conclusions Increased uric acid was associated with higher all-cause mortality risk in subjects with echocardiographic indices
of diastolic dysfunction, and with higher ischaemic stroke risk in persons with severely enlarged left atria.
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Introduction
Diastolic dysfunction (DD) is characterised by abnormal
cardiac relaxation, stiffness, or ﬁlling. It is closely associated
with heart failure with preserved ejection fraction (HFpEF),
a clinical syndrome where the patient suffers from symptoms
and signs of heart failure (HF) and has normal or only mildly
reduced ejection fraction.1 About half of all HF patients have
HFpEF.1 The prevalence of HFpEF in the HF population
increases, and the prognosis once hospitalised is on par with
that of HF with reduced ejection fraction (HFrEF).2 Contrary
to HFrEF, there is no medical treatment of proven beneﬁt
for HFpEF,1 although a recent study demonstrated a positive
effect of exercise and diet on exercise capacity in obese, el-
derly patients with clinically stable HFpEF.3 So far medical
therapy for HFpEF is mostly symptomatic and consists of
treating contributing factors and comorbidities such as hyper-
tension, volume overload, and atrial ﬁbrillation.1 There is
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evidence that DD progresses over time and is a risk factor for
the development of HFpEF.4 DD is commonly asymptomatic
and is associated with increased all-cause mortality.5 Thus,
there is a need for more knowledge about possibly modiﬁ-
able risk factors for adverse outcome in DD.
Elevated uric acid (UA) levels are associated with cardio-
vascular disease and death. In a previous population-based
cohort study, we showed that increased UA was associated
with elevated risk for all-cause mortality and ischaemic stroke
after 15 and 12 years of follow-up, respectively.6 In a meta-
analysis, hyperuricaemia was associated with high all-cause
mortality in HF patients.7 Furthermore, a recent study dem-
onstrated that hyperuricaemia was associated with increased
all-cause mortality in patients who were hospitalised for
HFpEF.8 However, the association between UA and DD re-
mains unclear. Because both DD and UA are associated with
increased risk of mortality, and hyperuricaemia is associated
with increased mortality in HF, it is of interest to address a
possible interaction between UA and DD, not the least be-
cause there is effective pharmacological treatment for
hyperuricaemia. We investigated the combined associations
between UA, markers of DD, and the endpoints incident myo-
cardial infarction, incident ischaemic stroke, and all-cause
mortality in a prospective, population-based cohort study
with 19 years follow-up.
Methods
Study population
The Tromsø Study is a series of population based prospective
surveys, conducted since 1974, with the participation of the
inhabitants of the municipality of Tromsø in Northern
Norway.9 The population of the present study is the partici-
pants of the Tromsø Study in 1994–95. In this fourth wave,
27 158 men and women attended (77% of eligible subjects).
Out of these, all participants aged 55–74 years, as well as
smaller, random samples of the other age groups 25–85 years
were invited to the more extensive second visit examination,
and 7965 subjects attended (75% of eligible subjects). Of
those, 7445 persons had their serum UA measured, and
3272 subjects had been randomly selected for echocardiogra-
phy. Put together, 3068 subjects underwent both UA mea-
surement and echocardiography. We excluded the persons
(n = 128) with diabetes at baseline (deﬁned as haemoglobin
A1c (HbA1c) ≥6.5%, non-fasting glucose ≥10.0 mmol/L, re-
ceiving anti-diabetic treatment or self-reported diabetes).
Thus, the ﬁnal cohort consisted of 1460 women and 1480
men. The University of Tromsø conducted the study in coop-
eration with The National Health Screening Service. The Re-
gional Committee for Medical and Health Research Ethics
approved this study (committee’s reference number
2009/2536-3), and all participants gave their informed and
written consent to participate. The Tromsø Study complies
with the Declaration of Helsinki.
Measurements
The participants provided information on diabetes, smoking
habits, physical activity, and current use of medication
through a self-administered questionnaire. Blood pressure
was recorded in triplicate, and we used the mean of the sec-
ond and the third measurement. We classiﬁed physical activ-
ity as active (≥1 h physical activity with prominent
perspiration or breathlessness per week) or inactive (all
others), and smoking habits as current smokers and non-
smokers. We calculated body mass index as weight (kg) /
height2 (m). Blood samples were non-fasting. The analysis of
UA was recently described.10 Creatinine was measured as pre-
viously described.11 We calculated the estimated glomerular
ﬁltration rate (eGFR) according to the CKD-EPI formula.12 De-
scriptions of measurements of lipids and HbA1c have been
published previously.13
Echocardiography
Two expert cardiologists and a medical doctor performed all
the echocardiography of the survey in 1994–95 using a
Vingmed CFM 750 (Vingmed Sound A/S, Horten, Norway),
and it was recently described in detail.14 We indexed left
atrial (LA) size by body surface area (BSA) calculated by
the Du Bois formula (BSA = [weight {kg} 0.425 × height
{cm} 0.725] × 0.007184).14
Diastolic dysfunction
We used LA size and mitral Doppler measurements as param-
eters of DD, and the cut-offs were set according to previously
published data.14 An upper limit of E-wave deceleration time
(EDT) as a measure of impaired relaxation was added accord-
ing to guidelines.15 We set the cut-off of isovolumetric relax-
ation time (IVRT, the duration of time between the end of
aortic ejection and the onset of mitral inﬂow) in line with
guidelines to detect restrictive left ventricular physiology.15
E/A ratio, the ratio of peak early Doppler mitral ﬂow velocity
(E-wave) to peak late Doppler mitral ﬂow velocity (A-wave),
was stratiﬁed into low (<0.75), normal (0.75–1.5) and high
(>1.5). We divided EDT, the deceleration time from peak to
end of early Doppler mitral ﬂow, into low (<140 ms), normal
(140–220 ms), and high (>220 ms). We stratiﬁed LA size into
normal (<2.2 cm/m2), moderately enlarged (2.2–2.79 cm/
m2), and severely enlarged (≥2.8 cm/m2). IVRT was either re-
duced (≤60 ms) or normal (>60 ms).
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Outcomes
The endpoints were all-cause mortality and ﬁrst ever fatal or
non-fatal myocardial infarction and ischaemic stroke, identi-
ﬁed by linkage to the diagnosis registry at the University Hos-
pital of North Norway and the National Causes of Death
Registry. An independent endpoint committee evaluated hos-
pital and out-of-hospital journals, autopsy records, and death
certiﬁcates to adjudicate each myocardial infarction and isch-
aemic stroke. Information on emigration from the municipal-
ity, from Norway, and date of death was obtained from the
National Registry of Norway. Endpoint registry is complete
through 31 December 2013 (19 years) for all-cause mortality
and through 31 December 2012 (18 years) for myocardial in-
farction and ischaemic stroke. For all-cause mortality data,
we censored for emigration from Norway. For myocardial in-
farction and ischaemic stroke, we censored for migration out
of the municipality or Norway, and death from other causes
than incident myocardial infarction and incident ischaemic
stroke, respectively.
Statistics
The baseline characteristics are given as mean  SD for the
continuous variables or number and percentage of total for
the categories. For each of the baseline characteristics, we
assessed the Pearson coefﬁcient for the correlation with
UA. We used Cox proportional hazards models to
investigate the relationship of UA and the echocardio-
graphic indices of DD with the endpoints all-cause mortality,
incident myocardial infarction, and incident ischaemic
stroke. Covariates were baseline values of sex, age, mean
systolic blood pressure, mean diastolic blood pressure, total
cholesterol, triglycerides, body mass index, current smoking,
physical activity, HbA1c, eGFR, and use of antihypertensive
medication including diuretics. We tested for the interaction
between UA and each echocardiographic marker of DD
using two-way cross products between the continuous UA
variable and indicator variables of each echocardiographic
marker of DD. Missing data were infrequent and random,
and therefore we chose not to use imputation methods to
account for missing data in this large cohort. We considered
a two-sided P-value of <0.05 signiﬁcant. The proportional
hazard assumptions were validated by visual inspection of
the log minus log survival plots. We did all the analyses
with SPSS software version 22.0 (IBM Corp. Released
2013. IBM SPSS Statistics for Windows, Version 22.0.
Armonk, NY: IBM Corp).
Results
Baseline characteristics
Table 1 shows the unadjusted baseline characteristics and
Pearson correlation coefﬁcients with UA for the 2940
Table 1 Unadjusted baseline characteristics of study population (n = 2940) and Pearson correlation with uric acid
SD or %
Pearson correlation
with UA
P for Pearson
correlation
Age, years 59.7 10.4 0.01 0.56
Sex Men 1480 49.7% 0.46 <0.001
Women 1460 50.3%
Systolic blood pressure, mm Hg 144.3 22.2 0.13 <0.001
Diastolic blood pressure, mm Hg 83.3 12.6 0.19 <0.001
BMI, kg/m2 25.9 3.9 0.32 <0.001
Uric acid μmol/L Men 359.1 84.9 — —
Women 277.6 71.7
Total cholesterol, mmol/L 6.72 1.28 0.08 <0.001
Triglycerides, mmol/L 1.68 1.02 0.43 <0.001
HbA1C, % 5.4 0.4 0.05 0.02
eGFR, mL/min/1.73 m2 93.1 13.2 0.19 <0.001
Daily smoker, n 967 32.9% 0.05 0.01
Use of antihypertensive drugs, n 428 14.6% 0.20 <0.001
Use of allopurinol, n 4 0.1% 0.04 0.03
Physical activity, n 659 22.4% 0.01 0.51
Left ventricular mass, g/m2 Men 107.0 27.9 0.22 <0.001
Women 90.8 22.7
Left atrial size, cm/m2 2.18 0.32 0.05 0.01
E/A ratio 1.05 0.36 0.06 0.001
E wave deceleration time, ms 200 43 0.04 0.03
Left ventricular isovolumic relaxation time, ms 104 20 0.12 <0.001
Left ventricular ejection fraction, % 75.0 7.8 0.06 0.004
Left ventricular ejection fraction < 50 %, n 9 0.3% 0.02 0.33
BMI, body mass index; HbA1c, haemoglobin A1c; eGFR, estimated glomerular ﬁltration rate; UA, uric acid.
The Tromsø Study 1994–2013.
The ﬁrst column in each stratum provides means for the continuous variables and numbers for the categories.
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participants. The echocardiographic indices of DD studied in
this article correlated weakly with UA, and among the
markers, IVRT correlated the strongest with UA.
Events
In our cohort of 2940 persons, a total of 1014 deaths from all
causes, 412 ﬁrst-ever myocardial infarctions, and 271 ﬁrst-
ever ischaemic strokes occurred during follow-up.
Interactions
Results from Cox proportional hazards models with multivar-
iable adjusted hazard ratio (HR) for all-cause mortality, myo-
cardial infarction, and ischaemic stroke, given for each
variable in the model, are displayed in Table 2. As echocardio-
graphic marker of DD, we present the analysis of E/A ratio.
Decreased E/A ratio, but not increased E/A ratio, was associ-
ated with increased risk of all-cause mortality, while this DD
index was not associated with myocardial infarction or
stroke. Elevated UA was associated with increased risk of
all-cause mortality and ischaemic stroke, but not risk of myo-
cardial infarction.
In these analyses with the indices of DD, UA interacted sig-
niﬁcantly with E/A ratio, EDT, and IVRT for the association
with all-cause mortality, and with LA size for ischaemic stroke.
This led us to stratify the cohort according to the
predetermined levels of each of these indices of DD and ex-
amine the effect of UA on the risk of outcomes. There was
no interaction between sex and echocardiographic markers
of DD or UA in these analyses.
Echocardiographic markers of DD modiﬁed the
associations between UA and the outcomes
Figures 1–4 show the results of multivariable Cox propor-
tional hazards models when the cohort was stratiﬁed accord-
ing to four echocardiographic markers of DD. HRs are per
59 μmol/L (1 mg/dL) UA increase at baseline. Included in
the ﬁgures is the number subjects and the number of events
of the outcome examined in each stratum.
Figure 1 shows that elevated UA was associated with in-
creased risk of all-cause mortality in subjects with E/A ratio
<0.75 (HR 1.12, 95% conﬁdence interval [CI] 1.00–1.25,
P = 0.04) and E/A ratio >1.5 (HR 1.51, 95% CI 1.09–2.09,
P = 0.01). Subjects with normal E/A ratio had no increased
risk of mortality with higher UA (HR 1.03, 95% CI 0.96–1.11,
P = 0.45); P for interaction between UA and the categorical
E/A ratio variable was 0.02.
Both subjects with EDT <140 ms (HR 1.46, 95% CI 1.01–
2.12, P = 0.04) and EDT >220 ms (HR 1.13, 95% CI 1.02–
Table 2 Multivariable Cox proportional hazard models of risk for all-cause mortality and adverse cardiovascular events
All-cause
mortality
Myocardial
infarction
Ischaemic
stroke
Hazard
ratio 95% CI
P
value
Hazard
ratio 95% CI
P
value
Hazard
ratio 95% CI
P
value
Sex (male vs. female) 1.42 [1.21–1.66] 0.000 2.05 [1.60–2.64] 0.000 1.28 [0.94–1.74] 0.121
Age (per year increase) 1.13 [1.11–1.14] 0.000 1.06 [1.04–1.08] 0.000 1.08 [1.06–1.11] 0.000
BMI (per kg/m2 increase) 0.98 [0.96–1.00] 0.055 1.01 [0.98–1.04] 0.525 0.99 [0.95–1.03] 0.545
Mean systolic blood pressure
(per 5 mm Hg increase)
1.01 [0.98–1.03] 0.688 1.04 [1.01–1.08] 0.023 1.04 [1.00–1.09] 0.066
Mean diastolic blood pressure
(per 5 mm Hg increase)
1.04 [1.01–1.09] 0.042 1.01 [0.95–1.07] 0.823 1.03 [0.95–1.11] 0.465
Total cholesterol (per
mmol/L increase)
0.97 [0.92–1.03] 0.313 1.17 [1.07–1.28] 0.001 0.96 [0.86–1.08] 0.488
Triglycerides (per
mmol/L increase)
0.97 [0.90–1.05] 0.503 0.99 [0.88–1.11] 0.841 1.04 [0.91–1.20] 0.538
eGFR (per
10 mL/min/1.73 m2 increase)
1.02 [0.95–1.09] 0.510 0.91 [0.83–1.00] 0.058 1.05 [0.92–1.21] 0.433
HbA1c (per % increase) 1.26 [1.04–1.52] 0.018 1.21 [0.90–1.62] 0.200 1.11 [0.78–1.60] 0.557
Smoker (yes vs. no) 2.00 [1.74–2.31] 0.000 1.70 [1.37–2.13] 0.000 1.45 [1.09–1.92] 0.011
Physically active (yes vs. no) 0.94 [0.79–1.13] 0.525 0.94 [0.72–1.23] 0.643 0.85 [0.60–1.20] 0.355
Use of antihypertensive
medication (yes vs. no)
1.27 [1.07–1.51] 0.005 0.98 [0.75–1.30] 0.914 1.27 [0.92–1.76] 0.154
Uric acid (per
59 μmol/L increase)
1.06 [1.00–1.13] 0.038 1.01 [0.93–1.10] 0.818 1.13 [1.02–1.25] 0.022
E/A ratio (<0.75 vs. 0.75–1.5) 1.31 [1.12–1.52] 0.001 1.10 [0.85–1.42] 0.457 1.09 [0.80–1.48] 0.592
(>1.5 vs. 0.75–1.5) 1.03 [0.73–1.47] 0.852 1.10 [0.67–1.79] 0.707 0.64 [0.30–1.38] 0.254
BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; HbA1c, haemoglobin A1C.
The Tromsø Study 1994–2013.
Covariates: Sex, age, BMI, mean systolic blood pressure, mean diastolic blood pressure, total cholesterol, triglycerides, eGFR, HbA1c,
current smoking, physical activity, use of antihypertensive medication, uric acid, E/A ratio.
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1.26, P = 0.02) experienced elevated risk of all-cause mortal-
ity with increasing UA, as demonstrated in Figure 2. Persons
with normal EDT did not have increased risk of mortality with
higher UA (HR 1.04, 95% CI 0.96–1.11, P = 0.35), and P for in-
teraction between UA and the categorical EDT variable
was 0.04.
The 61 subjects with IVRT ≤60 ms exhibited a nearly ﬁve-
fold rate of death with increasing UA (HR 4.98, 95% CI
2.02–12.26, P < 0.001), as displayed in Figure 3. The subjects
with IVRT >60 ms, who make up the rest of the cohort, also
had increased risk of death with increasing UA, but at a lower
rate (HR 1.07, 95% CI 1.01–1.13, P = 0.02), and P for interac-
tion between UA and the categorical IVTR variable was 0.004.
There were no signiﬁcant interactions between UA and the
categorical E/A ratio, EDT, or IVRT variables for neither
myocardial infarction nor ischaemic stroke.
Figure 1 Multivariable Cox proportional hazards model. Hazard ratios
per 59 μmol/L uric acid increase for all-cause mortality with low, normal,
and high E/A ratio. Covariates: Sex, age, body mass index, mean systolic
blood pressure, mean diastolic blood pressure, total cholesterol, triglycer-
ides, estimated glomerular ﬁltration rate, haemoglobin A1c, current
smoking, physical activity, and use of antihypertensive medication.
Abbreviations: e, events. The Tromsø Study 1994–2013.
Figure 2 Multivariable Cox proportional hazards model. Hazard ratios
per 59 μmol/L uric acid increase for all-cause mortality with low, normal,
and high E-wave deceleration time (EDT). Covariates: Sex, age, body mass
index, mean systolic blood pressure, mean diastolic blood pressure, total
cholesterol, triglycerides, estimated glomerular ﬁltration rate, haemoglobin
A1c, current smoking, physical activity, and use of antihypertensive medica-
tion. Abbreviations: e, events. The Tromsø Study 1994–2013.
Figure 3 Multivariable Cox proportional hazards model. Hazard ratios
per 59 μmol/L uric acid increase for all-cause mortality with low and nor-
mal isovolumic relaxation time (IVRT). Covariates: Sex, age, body mass in-
dex, mean systolic blood pressure, mean diastolic blood pressure, total
cholesterol, triglycerides, estimated glomerular ﬁltration rate, haemoglobin
A1c, current smoking, physical activity, and use of antihypertensive medica-
tion. Abbreviations: e, events. The Tromsø Study 1994–2013.
Figure 4 Multivariable Cox proportional hazards model. Hazard ratios
per 59 μmol/L uric acid increase for ischaemic strokewith normal, moderately
enlarged, and severely enlarged left atria (LA). Covariates: Sex, age, bodymass
index, mean systolic blood pressure, mean diastolic blood pressure, total
cholesterol, triglycerides, estimated glomerular ﬁltration rate, haemoglobin
A1c, current smoking, physical activity, and use of antihypertensive medica-
tion. Abbreviations: e, events. The Tromsø Study 1994–2013.
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Persons with LA size ≥2.8 cm/m2 had signiﬁcantly higher
risk of ischaemic stroke with increasing UA (HR 1.62, 95% CI
1.03–2.53, P = 0.04), as shown in Figure 4. The persons with
normal LA size also had increased risk of ischaemic stroke with
increasing UA, but at a lower rate (HR 1.26, 95% CI 1.10–1.43,
P = 0.001). UA was not associated with ischaemic stroke in per-
sons with moderately enlarged LA (HR 1.02, 95% CI 0.86–1.20,
P = 0.83), and P for interaction between UA and the categorical
LA size variable was 0.047. There were no signiﬁcant interac-
tions between the LA size variable and UA for the associations
with neither all-cause mortality nor myocardial infarction.
Discussion
In this prospective study of 1460 women and 1480 men from
the general population with nearly 20 years follow-up, we
found that elevated UA predicted all-cause mortality in per-
sons with echocardiographic indices of DD, compared with
persons without. Subjects with increased or decreased E/A
ratio, increased or decreased EDT, or reduced IVRT all had
higher risk of death during follow-up with increasing UA at
baseline. In persons with severely enlarged left atria, the risk
of ischaemic stroke was higher with elevated UA.
Hypertension
To our knowledge, the present study is the ﬁrst to demon-
strate an association between echocardiographic markers of
DD and higher risk of mortality and ischaemic stroke with in-
creasing UA in a general population. Hyperuricaemia is asso-
ciated with impaired survival in HF patients.16 Recently, a
longitudinal study showed that hyperuricaemia was related
to an increased risk of mortality in hospitalised patients
with HFpEF.8 UA is closely associated with hypertension; a
meta-analysis reported that higher UA was associated with
a statistically signiﬁcant elevation in incident hypertension.17
In a recent prospective cohort study, we demonstrated that
UA was associated with development of elevated blood pres-
sure in overweight subjects.10 Hypertension is also closely as-
sociated with DD,5 both being implicated in the development
of HFpEF.1 It is possible that the effect of UA on survival in
subjects with signs of DD, as demonstrated in this study, is
connected to the presence of hypertension. On the other
hand, all multivariable analyses in our study were adjusted
for systolic and diastolic blood pressure, as well as current
use of blood pressure lowering medication, and therefore ad-
ditional mechanisms are most likely in play.
Reactive oxygen species
With DD, there is abnormal cardiac relaxation, stiffness, or
ﬁlling. The mechanisms behind this are not clear. It has been
hypothesised that reactive oxygen species (ROS) limit nitric
oxide (NO) bioavailability, which in turn may eventually lead
to cardiac remodelling and DD, as well as endothelial
dysfunction.18 ROS is a by-product when the enzyme xan-
thine oxidase (XO) catalyses the reactions of hypoxanthine
to xanthine and xanthine to UA.19 Experimental studies have
implicated XO-derived ROS in the pathology of HF, both by
demonstrating increased XO activity in the failing heart and
by showing that XO inhibition improves survival in animal
models of HF.20 Recently, an experiment showed that male
mice fed a western diet (chow rich in fat, sucrose, and high-
fructose corn syrup) for 16 weeks developed hyperuricaemia,
along with cardiomyocyte hypertrophy, myocardial oxidative
stress, and impaired diastolic relaxation.21 XO inhibition with
allopurinol improved all the cardiac abnormalities, and the
authors argued that high XO activity, identiﬁed as a high
UA, was an instigator of DD. In our study, it is possible that
UA is a marker of XO activity, and hence oxidative stress that
contributes to a deterioration of DD and thus reduces sur-
vival. However, a convincing clinical beneﬁt of XO inhibition
in HF patients has yet to be demonstrated22. To date, no
randomised controlled trial has examined XO inhibition or
other UA lowering drugs in HFpEF patients or subjects
with DD.
Insulin resistance and diabetes
Another possible pathway explaining the association be-
tween UA and adverse outcome in subjects with DD may be
related to certain degrees of insulin resistance, which may
or may not occur with diabetes, and it is an important risk
factor for HFrEF and HFpEF.1 In diabetic cardiomyopathy,
DD is an early phenomenon.23 DD is common in diabetic
patients and is associated with the development of HF and in-
creased mortality.24 We recently showed that UA was associ-
ated with elevated fasting glucose in overweight subjects,10
and UA is epidemiologically associated with the development
of both insulin resistance25 and diabetes.26 Thus, although
participants with diabetes were excluded from the present
study, metabolic changes at an earlier stage of the continuum
may have played a part in the association between UA and
adverse outcomes in persons with DD.
Left atrium size
We found a signiﬁcant association between UA and ischaemic
stroke in participants with severely enlarged LA (≥2.8 cm/
m2). A previous study from our group showed that elevated
baseline UA is associated with increased risk of atrial ﬁbrilla-
tion,27 and another study recently demonstrated that LA size
≥2.8 cm/m2 was signiﬁcantly associated with increased risk of
incident atrial ﬁbrillation.14 It is conceivable that the
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association between severely enlarged LA and risk of ischae-
mic stroke is mediated through the risk for ischaemic stroke
posed by atrial ﬁbrillation. Hyperuricaemia is also associated
with endothelial dysfunction28, and endothelial dysfunction
is associated with increased risk of stroke in atrial ﬁbrillation,
as shown in one study where raised plasma levels of von
Willebrand factor, as a marker of endothelial dysfunction,
were predictive of stroke in patients with atrial ﬁbrillation.29
It is therefore possible that endothelial dysfunction
associated with hyperuricaemia could contribute to a pro-
thrombotic state in the appendages of severely enlarged atria
and thus is associated with increased risk of ischaemic stroke.
Study strengths and limitations
This study involves a large population-based study with a high
attendance rate and long follow-up, and an equal number of
men and women, which is a strength when DD is examined.
The ability to correct for confounders such as eGFR, tradi-
tional cardiovascular risk factors, and the use of antihyper-
tensive medication including diuretics also strengthens the
study. Endpoints have been thoroughly validated in each indi-
vidual through medical records. A shortcoming of this study
was that only a single measurement of serum UA was avail-
able. The blood samples were not fasting, and this may have
affected in particular the triglycerides. The Tromsø Study did
not acquire data on tissue Doppler in 1994–95, which could
have provided more information on DD, and our data lacked
LA volume measurements, so our estimation of LA size was
diameter based; this may be additional limitations. The fact
that our cohort was homogenous, largely consisting of
middle-aged, healthy Caucasians, can be viewed as both a
strength and a limitation; the external validity may be re-
duced while the internal validity is increased
In conclusion, higher baseline UA was a predictor of all-
cause mortality in subjects with reduced or increased E/A
ratio, reduced or increased EDT, and reduced IVRT. Elevated
baseline UA was associated with increased risk of ischaemic
stroke in subjects with severely enlarged LA.
Acknowledgements
We thank the late Prof. Ingrid Toft who helped conceive this
study. Your legacy lives on.
Conﬂict of interest
None declared.
Funding
This study was supported by grants from Northern Norway
Regional Health Authority (Helse Nord).
References
1. Yancy CW, Jessup M, Bozkurt B, Butler J,
Casey DE, Drazner MH, Fonarow GC,
Geraci SA, Horwich T, Januzzi JL,
Johnson MR, Kasper EK, Levy WC,
Masoudi FA, McBride PE, McMurray
JJV, Mitchell JE, Peterson PN, Riegel B,
Sam F, Stevenson LW, Tang WHW, Tsai
EJ, Wilkoff BL. 2013 ACCF/AHA Guide-
line for the Management of Heart Fail-
ure: a report of the American College
of Cardiology Foundation/American
Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol; 2013; 62:
e147–e239.
2. Paulus WJ, Tschope C, Sanderson JE,
Rusconi C, Flachskampf FA, Rademakers
FE, Marino P, Smiseth OA, Keulenaer G
De, Leite-Moreira AF, Borbely A, Edes I,
Handoko ML, Heymans S, Pezzali N,
Pieske B, Dickstein K, Fraser AG,
Brutsaert DL. How to diagnose diastolic
heart failure: a consensus statement on
the diagnosis of heart failure with
normal left ventricular ejection fraction
by the Heart Failure and Echocardiogra-
phy Associations of the European
Society of Cardiology. Eur Heart J
2007; 28: 2539–2550.
3. Kitzman DW, Brubaker P, Morgan T,
Haykowsky M, Hundley G, Kraus WE,
Eggebeen J, Nicklas BJ. Effect of caloric
restriction or aerobic exercise training
on peak oxygen consumption and qual-
ity of life in obese older patients with
heart failure with preserved ejection
fraction: a randomized clinical trial.
JAMA 2016; 315: 36–46.
4. Kane GC, Karon BL, Mahoney DW,
Redﬁeld MM, Roger VL, Jr JCB,
Jacobsen SJ. Progression of left ventric-
ular diastolic dysfunction and risk of
heart failure. JAMA 2011; 306:
856–863.
5. Redﬁeld MM, Jacobsen SJ, Burnett
JC, Mahoney DW, Bailey KR,
Rodeheffer RJ. Burden of systolic
and diastolic ventricular dysfunction
in the community: appreciating the
scope of the heart failure epidemic.
JAMA 2003; 289: 194–202.
6. Storhaug HM, Norvik J V, Toft I, Eriksen
BO, Løchen M-L, Zykova S, Solbu M,
White S, Chadban S, Jenssen T. Uric acid
is a risk factor for ischemic stroke and
all-cause mortality in the general popu-
lation: a gender speciﬁc analysis from
The Tromsø Study. BMC Cardiovasc
Disord 2013; 13: 115.
7. Tamariz L,HarzandA, PalacioA,VermaS,
Jones J, Hare J. Uric acid as a predictor of
all-cause mortality in heart failure: a
meta-analysis. Congest Heart Fail 2011;
17: 25–30.
8. Shimizu T, Yoshihisa A, Kanno Y,
Takiguchi M, Sato A, Miura S, Nakamura
Y, Yamauchi H, Owada T, Abe S, Sato T,
Suzuki S, OikawaM, Yamaki T, Sugimoto
K, Kunii H, Nakazato K, Suzuki H, Saitoh
S, Takeishi Y. Relationship of hyperurice-
mia with mortality in heart failure pa-
tients with preserved ejection fraction.
Am J Physiol—Hear Circ Physiol 2015;
309: H1123–H1129.
9. Jacobsen BK, Eggen AE, Mathiesen EB,
Wilsgaard T, Njølstad I. Cohort proﬁle:
the Tromsø study. Int J Epidemiol 2012;
41: 961–967.
10. Norvik JV, Storhaug HM, Ytrehus K,
Jenssen TG, Zykova SN, Eriksen BO,
Solbu MD. Overweight modiﬁes the lon-
gitudinal association between uric acid
and some components of the metabolic
syndrome: The Tromsø Study. BMC
Cardiovasc Disord; 2016; 16: 85.
160 J.V. Norvik et al.
ESC Heart Failure 2017; 4: 154–161
DOI: 10.1002/ehf2.12134
11. Kronborg J, Solbu MD, Njølstad I, Toft I,
Eriksen BO, Jenssen T. Predictors of
change in estimated GFR: a population-
based 7-year follow-up from the Tromsø
study. Nephrol Dial Transplant 2008; 23:
2818–2826.
12. Levey AS, Stevens LA, Schmid CH,
Zhang YL, Castro AF, Feldman HI, Kusek
JW, Eggers P, Lente F Van, Greene T,
Coresh J. A new equation to estimate
glomerular ﬁltration rate. Ann Intern
Med 2009; 150: 604–612.
13. Joseph J, Svartberg J, Njølstad I,
Schirmer H. Risk factors for type 2
diabetes in groups stratiﬁed according
to metabolic syndrome: A 10-year
follow-up of the Tromsø Study. Eur J
Epidemiol 2011; 26: 117–124.
14. Tiwari S, Schirmer H, Jacobsen BK,
Hopstock LA, Nyrnes A, Heggelund G,
Njolstad I, Mathiesen EB, Løchen ML.
Association between diastolic dysfunc-
tion and future atrial ﬁbrillation in the
Tromso Study from 1994 to 2010. Heart
2015; 101: 1301–1308.
15. Nagueh SF, Appleton CP, Gillebert TC,
Marino PN, Oh JK, Smiseth OA,
Waggoner AD, Flachskampf FA, Pellikka
PA, Evangelisa A. Recommendations for
the evaluation of left ventricular dia-
stolic function by echocardiography.
Eur J Echocardiogr 2009; 10: 165–193.
16. Anker SD, Doehner W, Rauchhaus M,
Sharma R, Francis D, Knosalla C, Davos
CH, Cicoira M, Shamim W, Kemp M,
Segal R, Osterziel KJ, Leyva F, Hetzer
R, Ponikowski P, Coats AJ. Uric acid
and survival in chronic heart failure: val-
idation and application in metabolic,
functional, and hemodynamic staging.
Circulation 2003; 107: 1991–1997.
17. Grayson PC, Young Kim S, Lavalley M,
Choi HK. Hyperuricemia and incident
hypertension: a systematic review and
meta-analysis. Arthritis Care Res 2011;
63: 102–110.
18. Zuo L, Chuang C, Hemmelgarn BT, Best
TM. Heart failure with preserved
ejection fraction: deﬁning the function
of ROS and NO. J Appl Physiol 2015;
119: 944–951.
19. Kang DH, Ha SK. Uric acid puzzle: dual
role as anti-oxidantand pro-oxidant.
Electrolyte Blood Press 2014; 12: 1–6.
20. Harzand A, Tamariz L, Hare JM. Uric
acid, heart failure survival, and the im-
pact of xanthine oxidase inhibition.
Congest Hear Fail 2012; 18: 179–182.
21. Jia G, Habibi J, Bostick BP, Ma L,
DeMarco VG, Aroor AR, Hayden MR,
Whaley-Connell AT, Sowers JR. Uric acid
promotes left ventricular diastolic dys-
function in mice fed a western diet.
Hypertension 2015; 65: 531–539.
22. Tamariz L, Hare JM. Xanthine oxidase
inhibitors in heart failure where do
we go from here? Circulation 2015;
131: 1741–1744.
23. Jia G, DeMarco VG, Sowers JR. Insulin
Resistance and Hyperinsulinaemia in
Diabetic Cardiomyopathy. Nat Rev
Endocrinol 2016; 12: 144–153.
24. From AM, Scott CG, Chen HH. The de-
velopment of heart failure in patients
with diabetes mellitus and pre-clinical
diastolic dysfunction. A population-
based study. J Am Coll Cardiol 2010;
55: 300–305.
25. Carnethon MR, Fortmann SP,
Palaniappan L, Duncan BB, Schmidt
MI, Chambless LE. Risk factors for pro-
gression to incident hyperinsulinemia:
the atherosclerosis risk in communities
study, 1987–1998. Am J Epidemiol
2003; 158: 1058–1067.
26. Dehghan A, Hoek M Van, Sijbrands EJG,
Hofman A, Wetteman JCM. High serum
uric acid as a novel risk factor for type
2 diabetes. Cardiovasc Metab Risk 2008;
31: 2007–2008.
27. Nyrnes A, Toft I, Njølstad I, Mathiesen
EB, Wilsgaard T, Hansen JB, Løchen
ML. Uric acid is associated with
future atrial ﬁbrillation: An 11-year
follow-up of 6308 men and women—
the Tromsø study. Europace 2014; 16:
320–326.
28. Mercuro G, Vitale C, Cerquetani E,
Zoncu S, Deidda M, Fini M, Rosano
GMC. Effect of hyperuricemia upon
endothelial function in patients at in-
creased cardiovascular risk. Am J
Cardiol 2004; 94: 932–935.
29. Conway DSG, Pearce LA, Chin BSP,
Hart RG, Lip GYH. Prognostic value of
plasma von Willebrand factor and
soluble P-selectin as indices of endo-
thelial damage and platelet activation
in 994 patients with nonvalvular
atrial ﬁbrillation. Circulation 2003;
107: 3141–3145.
Uric acid predicts mortality and ischaemic stroke in subjects with diastolic dysfunction: the Tromsø Study 1994–2013 161
ESC Heart Failure 2017; 4: 154–161
DOI: 10.1002/ehf2.12134
